GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Profitability Rank

Albireo Pharma (Albireo Pharma) Profitability Rank : 1 (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Profitability Rank?

Albireo Pharma has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Albireo Pharma's Operating Margin % for the quarter that ended in Sep. 2022 was -352.49%. As of today, Albireo Pharma's Piotroski F-Score is 3.


Competitive Comparison of Albireo Pharma's Profitability Rank

For the Biotechnology subindustry, Albireo Pharma's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Profitability Rank falls into.



Albireo Pharma Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Albireo Pharma has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Albireo Pharma's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-34.657 / 9.832
=-352.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Albireo Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Albireo Pharma Profitability Rank Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (Albireo Pharma) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Executives
Harford Simon N.r. officer: CFO and Treasurer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson officer: Chief Commercial Officer C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter officer: Chief Regulatory Officer C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson officer: Chief Operating Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham officer: Chief Human Resources Officer 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan officer: General Counsel C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson director 852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina director C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Albireo Pharma (Albireo Pharma) Headlines